Stay updated on Gemcitabine/Nab-paclitaxel ± FG-3019 Clinical Trial
Sign up to get notified when there's something new on the Gemcitabine/Nab-paclitaxel ± FG-3019 Clinical Trial page.

Latest updates to the Gemcitabine/Nab-paclitaxel ± FG-3019 Clinical Trial page
- CheckyesterdayChange DetectedNew Locations section added listing participating sites by state (Arizona, California, District of Columbia, Florida, Louisiana, Minnesota, Pennsylvania, Washington). The HHS Vulnerability Disclosure footer link was removed.SummaryDifference0.9%

- Check8 days agoNo Change Detected
- Check15 days agoNo Change Detected
- Check30 days agoChange DetectedFooter revision text updated from Revision: v3.2.0 to Revision: v3.3.2; overall page content and layout remain unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check37 days agoChange DetectedThe page removed a generic government funding status notice; this is a non-critical change that does not affect the study details or eligibility criteria. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check58 days agoChange DetectedResults and outcome data have been added, including safety and efficacy measures such as TEAEs/SAEs, surgical outcomes, and survival.SummaryDifference0.4%

- Check80 days agoChange DetectedCore content now includes an important government-operating-status notice and the site version is updated to v3.2.0, replacing the previous v3.1.0.SummaryDifference4%

- Check87 days agoChange DetectedUpdate indicates a new software/version release (v3.1.0) replacing the previous version (v3.0.2).SummaryDifference0.1%

Stay in the know with updates to Gemcitabine/Nab-paclitaxel ± FG-3019 Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Gemcitabine/Nab-paclitaxel ± FG-3019 Clinical Trial page.